Targeting CD47 as a Novel Immunotherapy for Breast Cancer
Can Chen, Runlu Wang, Xi Chen, Yulong Hou, Jingting Jiang
Abstract
Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor-targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety and efficacy in breast cancer. In this review, we summarized different therapeutic mechanisms targeting CD47 and its prognostic role and therapeutic value in breast cancer.
Topics & Concepts
MedicineBreast cancerBlockadeImmunotherapyCD47Immune checkpointCancerOncologyClinical trialCancer immunotherapyImmune systemTargeted therapyInternal medicineImmunologyReceptorPhagocytosis and Immune RegulationImmunotherapy and Immune ResponsesImmune cells in cancer